Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 52.76 as of 2026-09-10T17:20:40.000Z.
Consensus retrieved: 2026-09-10T03:25:13.459Z. This records retrieval, including cache reads, rather than vendor publication. A quote earlier than this retrieval cannot support current forward valuation.
Quote observation: 2026-09-10T17:20:40.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 461891cb7c254590516e49e38a0a038ebc025655c5473beed5b8d845ab71f3ca
Forward PE Ratio (52.76) = Close Price ($145.03) / Consensus Forward EPS ($2.75)
FORWARD PE RATIO
52.76
SECTOR MEDIAN · HEALTHCARE
18.92
median of 76 covered companies
CURRENT VS SECTOR MEDIAN
+178.86%
vs the sector median at left
Merck & Co., Inc.
Market Cap
$358.20B
Forward PE Ratio
52.76
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Merck & Co., Inc. (MRK) | $358.20B | 52.76 |
| UnitedHealth Group Incorporated (UNH)vs › | $355.66B | 19.82 |
| Roche Holding AG (RHHBY)vs › | $338.24B | N/A |
| AbbVie Inc. (ABBV)vs › | $446.12B | 18.00 |
| AstraZeneca PLC (AZN)vs › | $247.81B | 15.61 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $224.54B | 24.06 |
| Amgen Inc. (AMGN)vs › | $206.44B | 16.58 |
| Novo Nordisk A/S (NVO)vs › | $197.27B | N/A |
| Gilead Sciences, Inc. (GILD)vs › | $180.04B | N/A |
| Abbott Laboratories (ABT)vs › | $179.96B | 18.85 |
Trailing P/E
116.0
reported TTM EPS
Forward P/E
52.8
consensus next-FY EPS
The gap between the two multiples is the consensus growth expectation: analysts' forward EPS of $2.75 implies +120.0% EPS growth vs the reported trailing $1.25.
At today's $145.03 close, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $2.75 | $2.53 – $4.20 | 14 | 52.8x |
| 2027-12-31 | $9.55 | $9.10 – $9.93 | 14 | 15.2x |
| 2028-12-31 | $10.50 | $8.56 – $12.63 | 8 | 13.8x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
